EKOS™ Endovascular System
Introducing EKOS+
Same procedure, now 50% more powerful1
With 50% more ultrasound power and 32% more lysis than EKOS1, the new EKOS+ catheter builds on the EKOS legacy. It provides physicians more confidence to efficiently treat PE patients with lower lytic doses.
Key Resources
Product description
Ultrasonic core technology
- Minimally invasive, 15-minute procedure that is quick to perform
- Lytic agent: as low as 8 mg tPA used2
- Ultrasonic waves accelerate clot dissolution by unwinding and thinning fibrin strands to expose more drug receptor sites; acoustic streaming drives the drug deeper into the clot for safe dissolution
Reimbursement information
- Bench data on File
- Tapson V et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism. JACC: Cardiovascular Interventions 2018; 11(14):1401-1410.